Work

Adjuvant High-Dose Interferon-α for Resected Melanoma in a Patient with HIV Infection

Year: 2010

Type: article

Abstract: Adjuvant interferon (IFN)-alpha remains the standard adjuvant therapy for intermediate and high-risk melanoma after definitive surgical resection. Data addressing the role and safety of adjuvant immunotherapy in HIV-infected patients with melanoma are lacking. We report on an HIV(+) patient who received IFN-alpha as adjuvant treatment for high-risk melanoma. To our knowledge, this is the first reported case of such an approach.

Source: The Oncologist

DOI: 10.1634/theoncologist.2009-0335

Authors: Nakhle S. Saba, Thomas J. George, Brian C. Boulmay

Institutions: Tulane University, University of Florida, Louisiana State University Health Sciences Center New Orleans

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2134501231